|
시장보고서
상품코드
2088613
카테터 시장 : 제품별, 제품 유형별, 소재별, 코팅별, 최종 사용자별, 용도별 - 세계 시장 예측(2026-2032년)Catheters Market by Product, Type, Material, Coating, End User, Application - Global Forecast 2026-2032 |
||||||
360iResearch
카테터 시장은 2032년까지 연평균 복합 성장률(CAGR) 7.68%로 성장해 507억 2,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 302억 1,000만 달러 |
| 추정 연도(2026년) | 324억 1,000만 달러 |
| 예측 연도(2032년) | 507억 2,000만 달러 |
| CAGR(%) | 7.68% |
카테터 시장은 의료기기의 중요한 분야로, 요도 카테터, 혈관 접근용 카테터, 심혈관용 카테터, 신경혈관용 기기, 투석용 카테터 및 특수 배액 제품 등을 포괄합니다. 수요를 뒷받침하고 있는 것은 심혈관 질환, 만성 신장 질환, 요폐, 암 치료, 당뇨병 관련 합병증, 노화에 따른 운동 기능 제한 등으로 인한 부담 증가이며, 이 모든 요인이 병원, 외래수술센터(ASC), 장기 요양 시설, 재택치료 분야에서 카테터 사용 확대로 이어지고 있습니다.
카테터 시장은 수량 위주의 조달에서 가치를 기반으로 한 의료기기 선정으로 전환되고 있습니다. 병원에서는 감염 위험을 줄이고, 시술 시간을 단축하며, 환자의 편안함을 높이고, 표준화된 치료 과정을 지원하는 카테터를 우선적으로 도입하고 있습니다. 이에 따라 항균성 요도 카테터, 친수성 간헐적 카테터, 말초 삽입형 중심정맥 카테터, 첨단 전기생리학적 카테터, 약물 코팅 풍선 카테터 및 영상 유도형 혈관 접근 솔루션의 도입이 가속화되고 있습니다.
인공지능(AI)은 제품 설계, 시술 계획, 제조 품질, 임상 의사결정 지원 등 카테터 생태계 전반에 영향을 미치기 시작했습니다. 개발 단계에서는 AI를 활용한 시뮬레이션 및 계산 모델링을 통해 고비용의 시제품 제작에 앞서 카테터 샤프트의 유연성, 선단 형상, 코팅 성능 및 소재 선정의 최적화가 가능해집니다. 생산 단계에서는 머신 비전과 예측 분석이 결함 감지, 공정 관리, 로트 단위의 품질 모니터링을 지원합니다.
북미는 높은 시술 건수, 확립된 보험 환급 제도, 강력한 병원 구매 네트워크, 그리고 혈관 카테터, 요로 카테터, 전기생리학용 카테터, 신경혈관 카테터, 투석 카테터의 광범위한 사용 덕분에 여전히 주요 카테터 시장으로 자리 잡고 있습니다. 미국은 FDA 규정에 따른 제품 개발, 감염 관리 의무화, 저침습 심혈관 및 중재적 방사선학 시술의 급속한 보급을 통해 해당 지역의 혁신을 주도하고 있습니다. 한편, 캐나다는 품질, 안전성 및 공공 조달의 효율성을 중시하고 있습니다.
아세안 시장에서는 각국 정부가 병원의 수용 능력, 국민건강보험, 그리고 현지 의료 기술 생태계에 대한 투자를 추진하고 있어 그 중요성이 점점 더 커지고 있습니다. 수요가 가장 높은 것은 필수적인 요로용, 혈관 접근용, 투석용 및 응급구명용 카테터이며, 고가 제품의 도입은 주요 도시의 병원 및 민간 의료기관 네트워크에 집중되어 있습니다. 조달 결정에 있어서는 의료기기의 신뢰성, 임상의의 교육, 무균 관리, 그리고 유통업체의 서비스 범위가 점점 더 중요하게 여겨지고 있습니다.
미국은 혁신의 활발함, 시술 건수, 상품화 속도 면에서 카테터 시장을 선도하고 있으며, 비뇨기과 치료, 심혈관 중재술, 투석, 혈관 접근, 신경혈관 용도 등 모든 분야에서 견조한 수요가 나타나고 있습니다. 캐나다는 이에 발맞추어 안전성을 중시하는 조달과, 증거에 기반한 감염 예방 대책의 적극적인 도입을 추진하고 있습니다. 멕시코와 브라질은 라틴아메리카의 주요 시장이며, 병원 확장, 민간 부문의 성장, 만성 질환 관리로 인해 비용 대비 효과가 뛰어난 프리미엄 카테터 솔루션에 대한 수요가 증가하고 있습니다.
업계 리더는 측정 가능한 임상적 위험, 특히 감염, 혈전증, 폐색, 삽입 실패, 이물질 부착 및 환자의 불편감을 해결하는 차별화된 카테터 설계를 우선시해야 합니다. 제품 로드맵에서는 항균 표면, 친수성 코팅, 밀폐형 배액 시스템, 초음파 대응 소재, 뒤틀림 방지 설계 및 인체공학에 기반한 자가 카테터 삽입 기능을 검증된 임상 평가 지표 및 실제 임상 증거와 일치시켜야 합니다.
본 요약본은 규제 지침, 임상 기준, 병원 내 감염 예방 우선순위, 인구통계 지표, 만성 질환 유병률 동향, 시술 도입 패턴, 보험 급여 환경, 의료기기 기술 동향 등, 일반적으로 공개되고 업계에서 인정받는 근거를 통합한 2차 조사 프레임워크에 기초하여 작성되었습니다. 검토 대상 정보원에는 정부 보건 기관, 국제 보건 기구, 동료 심사를 거친 임상 문헌, 규제 당국, 전문적인 임상 지침, 그리고 공개적으로 기록된 제품 및 기술 개발이 포함됩니다.
카테터 시장은 기술 주도형이며 치료 성과를 중시하는 분야로 진화하고 있으며, 안전성, 근거, 그리고 사용 편의성이 경쟁 우위를 결정짓는 요소가 되고 있습니다. 성장을 가속하는 요인으로는 만성 질환 유병률, 고령화, 저침습 시술, 투석 확대, 중환자실 이용, 혈관 접근에 대한 수요, 그리고 재택 치료 모델로의 전환 등을 들 수 있습니다.
The Catheters Market is projected to grow by USD 50.72 billion at a CAGR of 7.68% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 30.21 billion |
| Estimated Year [2026] | USD 32.41 billion |
| Forecast Year [2032] | USD 50.72 billion |
| CAGR (%) | 7.68% |
The catheter market is a critical segment of medical devices, spanning urinary catheters, vascular access catheters, cardiovascular catheters, neurovascular devices, dialysis catheters, and specialty drainage products. Demand is supported by the rising burden of cardiovascular disease, chronic kidney disease, urinary retention, cancer care, diabetes-related complications, and age-associated mobility limitations, all of which increase catheter utilization across hospitals, ambulatory surgical centers, long-term care facilities, and home healthcare.
Market development is also shaped by infection prevention priorities. Catheter-associated urinary tract infections and catheter-related bloodstream infections remain major quality, safety, and cost concerns for health systems, increasing the value of antimicrobial coatings, hydrophilic surfaces, closed-system designs, ultrasound-guided placement, and evidence-based maintenance protocols. As payers and regulators emphasize outcomes, catheter manufacturers are competing on safety, ease of insertion, biocompatibility, durability, and verified reduction in complications.
The catheter landscape is shifting from volume-driven procurement toward value-based device selection. Hospitals are prioritizing catheters that reduce infection risk, shorten procedure time, improve patient comfort, and support standardized care pathways. This is accelerating adoption of antimicrobial urinary catheters, hydrophilic intermittent catheters, peripherally inserted central catheters, advanced electrophysiology catheters, drug-coated balloon catheters, and image-guided vascular access solutions.
At the same time, care delivery is moving beyond acute settings. Home infusion, peritoneal dialysis, intermittent self-catheterization, and chronic disease management are creating demand for devices that are easier to use, packaged for sterile handling, and compatible with remote care models. Regulatory scrutiny under FDA quality system expectations and the EU Medical Device Regulation is reinforcing the need for robust clinical evidence, post-market surveillance, traceability, human factors validation, and supplier resilience.
Artificial intelligence is beginning to influence the catheter ecosystem across product design, procedure planning, manufacturing quality, and clinical decision support. In development, AI-enabled simulation and computational modeling can help optimize catheter shaft flexibility, tip geometry, coating performance, and material selection before expensive prototyping. In production, machine vision and predictive analytics support defect detection, process control, and lot-level quality monitoring.
Clinically, AI is most relevant where catheters intersect with imaging and workflow. Algorithms that assist ultrasound guidance, vessel assessment, arrhythmia mapping, robotic navigation, and complication prediction can improve procedural consistency. AI-enabled risk scoring can also support early identification of patients at higher risk of catheter-associated infection, thrombosis, or occlusion, aligning catheter selection and maintenance protocols with evidence-based prevention.
North America remains a major catheter market due to high procedure volumes, established reimbursement, strong hospital purchasing networks, and broad use of vascular, urinary, electrophysiology, neurovascular, and dialysis catheters. The United States leads regional innovation through FDA-regulated product development, infection-control mandates, and rapid adoption of minimally invasive cardiovascular and interventional radiology procedures, while Canada emphasizes quality, safety, and public procurement efficiency.
Europe is shaped by aging demographics, strong urology and cardiology care pathways, and the compliance requirements of the EU Medical Device Regulation, which is increasing the importance of clinical evidence, post-market performance, and product traceability. Asia-Pacific is an expanding opportunity supported by hospital infrastructure investment, growing chronic disease burden, and rising access to dialysis, cardiac interventions, and catheter-based therapies in China, India, Japan, South Korea, ASEAN markets, and Australia.
Latin America, the Middle East, and Africa present demand opportunities tied to expanding private healthcare, public hospital modernization, and increasing adoption of infection prevention products. Brazil and Mexico anchor Latin American demand, the GCC drives high-acuity catheter adoption through advanced hospital systems, and African markets remain focused on access, affordability, clinical training, and supply continuity for essential catheter categories.
ASEAN markets are gaining relevance as governments invest in hospital capacity, universal health coverage, and local medical technology ecosystems. Demand is strongest for essential urinary, vascular access, dialysis, and critical care catheters, with premium adoption concentrated in major urban hospitals and private networks. Procurement decisions increasingly weigh device reliability, clinician training, sterile handling, and distributor coverage.
The GCC is characterized by advanced tertiary care, high diabetes and cardiovascular disease prevalence, and strong demand for premium vascular, urology, dialysis, and interventional catheters. The European Union continues to influence global catheter standards through MDR compliance, environmental procurement expectations, and evidence requirements. BRICS countries combine large patient pools with expanding manufacturing ambitions and growing hospital capacity, while the G7 leads in innovation, reimbursement sophistication, and high-value procedures. NATO member markets, overlapping with several G7 and EU countries, benefit from resilient healthcare infrastructure and strategic emphasis on secure medical supply chains.
The United States is the leading catheter market by innovation intensity, procedure volume, and commercialization speed, with strong demand across urinary care, cardiovascular interventions, dialysis, vascular access, and neurovascular applications. Canada follows with safety-focused procurement and strong adoption of evidence-based infection prevention. Mexico and Brazil are key Latin American markets where hospital expansion, private-sector growth, and chronic disease management are increasing demand for cost-effective and premium catheter solutions.
In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature demand supported by aging populations, high cardiovascular procedure volumes, established dialysis networks, and structured urology care, while Russia remains influenced by import substitution, pricing pressure, and hospital modernization needs. China is scaling rapidly through local manufacturing and hospital investment, India offers high-volume demand driven by access expansion and affordability, Japan emphasizes advanced technology and quality, Australia supports premium adoption through strong clinical standards, and South Korea combines high procedure capacity with digital health readiness.
Industry leaders should prioritize differentiated catheter designs that address measurable clinical risks, especially infection, thrombosis, occlusion, insertion failure, encrustation, and patient discomfort. Product roadmaps should align antimicrobial surfaces, hydrophilic coatings, closed drainage systems, ultrasound-compatible materials, kink-resistant designs, and ergonomic self-catheterization features with validated clinical endpoints and real-world evidence.
Commercial strategies should balance premium innovation with affordability. Manufacturers need region-specific portfolios, resilient supply chains, regulatory-ready documentation, and clinician education programs that improve placement technique and catheter maintenance. Partnerships with hospitals, home healthcare providers, dialysis networks, and digital health platforms can strengthen adoption. Leaders should also invest in AI-enabled quality control, sustainability initiatives, human factors engineering, and post-market data systems to meet payer, provider, and regulator expectations.
This executive summary is built from a secondary research framework that synthesizes publicly available and industry-recognized evidence, including regulatory guidance, clinical standards, hospital infection-prevention priorities, demographic indicators, chronic disease prevalence trends, procedure adoption patterns, reimbursement environments, and medical device technology dynamics. Sources considered include government health agencies, international health organizations, peer-reviewed clinical literature, regulatory bodies, professional clinical guidelines, and publicly documented product and technology developments.
The analysis evaluates catheter demand by product category, care setting, application, end user, region, economic group, and key country. Insights are validated through triangulation of epidemiological drivers, healthcare infrastructure maturity, procurement behavior, technology adoption, infection-control requirements, and regulatory trends. The methodology emphasizes data-backed interpretation while avoiding unsupported market claims, market sizing, market share statements, forecasts, or unverified competitive assertions.
The catheter market is evolving into a technology-led, outcomes-focused sector where safety, evidence, and usability determine competitive advantage. Growth drivers include chronic disease prevalence, aging populations, minimally invasive procedures, dialysis expansion, critical care utilization, vascular access needs, and the shift toward home-based treatment models.
Organizations that combine clinically validated product innovation with regulatory discipline, manufacturing quality, supply chain resilience, and market-specific affordability will be best positioned to support sustainable adoption. As artificial intelligence, advanced coatings, image-guided placement, and patient-centered designs mature, catheter manufacturers have a significant opportunity to improve care quality while reducing preventable complications across global healthcare systems.